This page is intended to provide updates for participants on the work that has been done with their samples and data. We will keep this page updated with research results, reports and plans.
During its first 3 months, the ISARIC4C consortium expanded from the initial 34 co-investigators to more than 150 active contributors, and provides a data and sampling infrastructure for follow-up of COVID cases in the P-HOSP consortium.
As well as these outputs, see the dynamic report of age, sex, and 28 day status of patients admitted with COVID.
BMJ 2020;370:m3339 The ISARIC 4C prognostic score Using data from 57,824 hospital admissions, w...
Nature Immunology (4th September 2020) Immune cells target many different parts of the virus ...
BMJ: 2020; 369 Quantifying the problem Within weeks of being funded, we produced the largest st...
BMJ 2020;370:m3249 Clinical characterisation of Covid-19 in children We have comprehensively ch...
MedRxiv August 16th 2020. Because of the large scale of the ISARIC-4C study, we were able to d...
SSRN July 2020 Impact of ethnicity We have carefully studied the effect of ethnicity on outcome...
MedRxiv September 2020 Genetic mechanisms of severe Covid-19 We have discovered multiple genes ...
MedRxiv May 2020 We proposed and established a Diagnostic Evaluation Platform at the University ...
MedRxiv June 2020 Supporting autopsy work ISARIC 4C resources and consortium partners supported...
The Remdesivir Statistical Analysis Plan was approved on 16 December 2020.
Setting the standard ISARIC 4C defined the international reference standard for SARS-CoV-2 serol...
Medrxiv June 2020 Transmission dynamics of COVID-19 We have explored the mechanisms of viral tr...